Saturday 19 May 2018

Aortech International . 2018 & Beyond

Biomerics and ATL Technology today announced they launched a joint venture to acquire Catheter Research, including its assets in Indianapolis and Costa Rica.
Catheter Research Inc manufactures interventional catheters, tube sets and other assemblies for medical devices, the companies said. The company has specific expertise in tube extrusion, catheter assembly and final FDA product packaging for sterilization, and also sells its own catheter line under the brand Thomas Medical.
“Through the addition of CRI, we are in a position to serve the medical device industry at an even higher level. This expansion of our global network offers numerous benefits to both national and international OEMs. Now, combining ATLs connector know-how with CRI’s catheter capabilities, we will make optimal use of our expertise and specialties relating to catheters and custom engineering in delivering a best-in-class product,” ATL CEO Brad Brown said in a prepared statement.
The companies said that existing employees at both of CRI’s facilities will work closely with ATL and Biomerics during integration, and that there are plans to expand CRI’s Costa Rica operations.
“This acquisition is consistent with Biomerics’ overall strategy to expand and invest in additional production and engineering capabilities to develop a global competitive advantage. CRI’s products and technology complement our current portfolio in the medical space and will broaden our product offering for suppliers around the world,” Biomerics CEO Travis Sessions said in a press release.

                                                                                                                   May 2018
-------------------------------------------------------------------------------
We have the opportunity of putting past issues behind us and building on the core IP within the business. As part of this "fresh start", I am delighted to welcome Stockdale Securities as our new Nominated Adviser and broker and look forward to working with them to help AorTech reach its true potential.

Bill Brown, Chairman                                                                                                      11 December 2017
------------------------------------
bbr391   20/05/2018

As far as we can determine Biomerics is now worth north of £35 million . Of which at least 10% can be ascribed to Aortech Or £1 per share and not today`s 50p .
There is also the little matter of the court case victory ( possibly £2million cash ).
 OR possible £2 per share

That said It is possible that a new way forward has been found by Bill & the team possible £5 - £20
It`s good to have a pipe dream for Elasteon ...................................

No comments:

Post a Comment